Synergistic Effect between Usnic Acid and Polymyxin B against Resistant Clinical Isolates of Pseudomonas aeruginosa
The present study aimed to characterize the susceptibility profile of Pseudomonas aeruginosa and Acinetobacter spp. clinical isolates to polymyxin B in a public hospital in Recife-PE, Brazil, between the years of 2018 and 2019, as well as to search for the presence of the mcr-1 gene and evaluate the...
Gespeichert in:
| Veröffentlicht in: | Evidence-based complementary and alternative medicine 2020, Vol.2020 (2020), p.1-9 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 9 |
|---|---|
| container_issue | 2020 |
| container_start_page | 1 |
| container_title | Evidence-based complementary and alternative medicine |
| container_volume | 2020 |
| creator | Vieira Maciel, Maria Amélia da Silva, Adriana Maria Costa Marques da Silva, Wagner Roberto Cirilo Costa-Junior, Sérgio Dias Cavalcanti, Isabella Macário Ferro |
| description | The present study aimed to characterize the susceptibility profile of Pseudomonas aeruginosa and Acinetobacter spp. clinical isolates to polymyxin B in a public hospital in Recife-PE, Brazil, between the years of 2018 and 2019, as well as to search for the presence of the mcr-1 gene and evaluate the interaction between polymyxin B and usnic acid against these isolates. The strains were identified using the BD Phoenix™ automated system and the agar-spot test was used to determine the susceptibility profile to polymyxin B. The minimum inhibitory concentrations (MICs) of usnic acid and polymyxin B were determined through the broth microdilution method according to the Clinical and Laboratory Standards Institute (CLSI). Subsequently, Polymerase Chain Reaction (PCR) was performed to detect the mcr-1 gene in the isolates. The interaction between usnic acid and polymyxin B was evaluated by the Checkerboard assay. Among 34 isolates of P. aeruginosa, 26.5% (9/34) were positive for the polymyxin B agar-spot test, and 11.8% (4/34) presented an intermediate susceptibility (MIC = 4 μg/mL), while 14.7% (5/34) presented antimicrobial resistance with MIC values ranging from 8 to 32 μg/mL. Among 38 isolates of Acinetobacter spp., 13.2% (5/38) were positive for the polymyxin B agar-spot test and all of them were resistant to polymyxin B with a MIC value > 32 μg/mL. The mcr-1 gene was not detected in the clinical isolates. Regarding usnic acid, it presented a moderate antibacterial activity against two P. aeruginosa isolates (MIC = 250 μg/mL) and no activity was detected against the others. A synergistic effect between usnic acid and polymyxin B was observed against three clinical isolates of P. aeruginosa which were resistant to polymyxin B (FICI ≤ 0.5). Therefore, it was possible to observe that usnic acid is a promising candidate to be used in combination with polymyxin B against infections caused by resistant P. aeruginosa. |
| doi_str_mv | 10.1155/2020/9852145 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7441413</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A639994777</galeid><sourcerecordid>A639994777</sourcerecordid><originalsourceid>FETCH-LOGICAL-c476t-5ef7427ceb4ed823ce2943a4a84ce8a1fa641dfafac2f928c073750c69fbf72c3</originalsourceid><addsrcrecordid>eNqF0c1rFDEYBvBBFFurN88S8CLYtfmaSXIR1qXVQsGiFryFdzNvpikzSTuZse5_b5ZdWvTiKSH55UnCU1WvGf3AWF2fcMrpidE1Z7J-Uh0yJdlCcq2fPszVz4PqRc43lHKjlHpeHQiupTFUHVb5-ybi2IU8BUdOvUc3kTVO94iRXOVYFpcutARiSy5Tvxk2v0Mknwh0EGKeyDfM5SjEiaz6UDT05DynHibMJHlymXFu05AiZAI4zl2IKcPL6pmHPuOr_XhUXZ2d_lh9WVx8_Xy-Wl4snFTNtKjRq_J4h2uJrebCITdSgAQtHWpgHhrJWg8eHPeGa0eVUDV1jfFrr7gTR9XHXe7tvB6wdRinEXp7O4YBxo1NEOzfOzFc2y79skpKJpkoAe_2AWO6mzFPdgjZYd9DxDRny6VQWkplaKFv_6E3aR5j-d5WNaIgYx5VBz3aEH0q97ptqF02oghZ-inqeKfcmHIe0T88mVG77dxuO7f7zgt_v-PXIbZwH_6n3-w0FoMeHjWrtVK1-ANZKbWE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2436347999</pqid></control><display><type>article</type><title>Synergistic Effect between Usnic Acid and Polymyxin B against Resistant Clinical Isolates of Pseudomonas aeruginosa</title><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library (Open Access Collection)</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Vieira Maciel, Maria Amélia ; da Silva, Adriana Maria Costa Marques ; da Silva, Wagner Roberto Cirilo ; Costa-Junior, Sérgio Dias ; Cavalcanti, Isabella Macário Ferro</creator><contributor>Kuete, Victor ; Victor Kuete</contributor><creatorcontrib>Vieira Maciel, Maria Amélia ; da Silva, Adriana Maria Costa Marques ; da Silva, Wagner Roberto Cirilo ; Costa-Junior, Sérgio Dias ; Cavalcanti, Isabella Macário Ferro ; Kuete, Victor ; Victor Kuete</creatorcontrib><description>The present study aimed to characterize the susceptibility profile of Pseudomonas aeruginosa and Acinetobacter spp. clinical isolates to polymyxin B in a public hospital in Recife-PE, Brazil, between the years of 2018 and 2019, as well as to search for the presence of the mcr-1 gene and evaluate the interaction between polymyxin B and usnic acid against these isolates. The strains were identified using the BD Phoenix™ automated system and the agar-spot test was used to determine the susceptibility profile to polymyxin B. The minimum inhibitory concentrations (MICs) of usnic acid and polymyxin B were determined through the broth microdilution method according to the Clinical and Laboratory Standards Institute (CLSI). Subsequently, Polymerase Chain Reaction (PCR) was performed to detect the mcr-1 gene in the isolates. The interaction between usnic acid and polymyxin B was evaluated by the Checkerboard assay. Among 34 isolates of P. aeruginosa, 26.5% (9/34) were positive for the polymyxin B agar-spot test, and 11.8% (4/34) presented an intermediate susceptibility (MIC = 4 μg/mL), while 14.7% (5/34) presented antimicrobial resistance with MIC values ranging from 8 to 32 μg/mL. Among 38 isolates of Acinetobacter spp., 13.2% (5/38) were positive for the polymyxin B agar-spot test and all of them were resistant to polymyxin B with a MIC value > 32 μg/mL. The mcr-1 gene was not detected in the clinical isolates. Regarding usnic acid, it presented a moderate antibacterial activity against two P. aeruginosa isolates (MIC = 250 μg/mL) and no activity was detected against the others. A synergistic effect between usnic acid and polymyxin B was observed against three clinical isolates of P. aeruginosa which were resistant to polymyxin B (FICI ≤ 0.5). Therefore, it was possible to observe that usnic acid is a promising candidate to be used in combination with polymyxin B against infections caused by resistant P. aeruginosa.</description><identifier>ISSN: 1741-427X</identifier><identifier>EISSN: 1741-4288</identifier><identifier>DOI: 10.1155/2020/9852145</identifier><identifier>PMID: 32849907</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Publishing Corporation</publisher><subject>Acinetobacter ; Antibacterial activity ; Antimicrobial resistance ; Bacteria ; Bacteriology ; Clinical isolates ; Deoxyribonucleic acid ; DNA ; Drug resistance in microorganisms ; E coli ; Genes ; Gram-negative bacteria ; Microorganisms ; Minimum inhibitory concentration ; Nosocomial infections ; Pathogens ; Polymerase chain reaction ; Polymyxin B ; Pseudomonas aeruginosa ; Usnic acid</subject><ispartof>Evidence-based complementary and alternative medicine, 2020, Vol.2020 (2020), p.1-9</ispartof><rights>Copyright © 2020 Sérgio Dias da Costa Júnior et al.</rights><rights>COPYRIGHT 2020 John Wiley & Sons, Inc.</rights><rights>Copyright © 2020 Sérgio Dias da Costa Júnior et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. http://creativecommons.org/licenses/by/4.0</rights><rights>Copyright © 2020 Sérgio Dias da Costa Júnior et al. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c476t-5ef7427ceb4ed823ce2943a4a84ce8a1fa641dfafac2f928c073750c69fbf72c3</citedby><cites>FETCH-LOGICAL-c476t-5ef7427ceb4ed823ce2943a4a84ce8a1fa641dfafac2f928c073750c69fbf72c3</cites><orcidid>0000-0002-7889-3502 ; 0000-0002-2501-3284</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7441413/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7441413/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,4024,27923,27924,27925,53791,53793</link.rule.ids></links><search><contributor>Kuete, Victor</contributor><contributor>Victor Kuete</contributor><creatorcontrib>Vieira Maciel, Maria Amélia</creatorcontrib><creatorcontrib>da Silva, Adriana Maria Costa Marques</creatorcontrib><creatorcontrib>da Silva, Wagner Roberto Cirilo</creatorcontrib><creatorcontrib>Costa-Junior, Sérgio Dias</creatorcontrib><creatorcontrib>Cavalcanti, Isabella Macário Ferro</creatorcontrib><title>Synergistic Effect between Usnic Acid and Polymyxin B against Resistant Clinical Isolates of Pseudomonas aeruginosa</title><title>Evidence-based complementary and alternative medicine</title><description>The present study aimed to characterize the susceptibility profile of Pseudomonas aeruginosa and Acinetobacter spp. clinical isolates to polymyxin B in a public hospital in Recife-PE, Brazil, between the years of 2018 and 2019, as well as to search for the presence of the mcr-1 gene and evaluate the interaction between polymyxin B and usnic acid against these isolates. The strains were identified using the BD Phoenix™ automated system and the agar-spot test was used to determine the susceptibility profile to polymyxin B. The minimum inhibitory concentrations (MICs) of usnic acid and polymyxin B were determined through the broth microdilution method according to the Clinical and Laboratory Standards Institute (CLSI). Subsequently, Polymerase Chain Reaction (PCR) was performed to detect the mcr-1 gene in the isolates. The interaction between usnic acid and polymyxin B was evaluated by the Checkerboard assay. Among 34 isolates of P. aeruginosa, 26.5% (9/34) were positive for the polymyxin B agar-spot test, and 11.8% (4/34) presented an intermediate susceptibility (MIC = 4 μg/mL), while 14.7% (5/34) presented antimicrobial resistance with MIC values ranging from 8 to 32 μg/mL. Among 38 isolates of Acinetobacter spp., 13.2% (5/38) were positive for the polymyxin B agar-spot test and all of them were resistant to polymyxin B with a MIC value > 32 μg/mL. The mcr-1 gene was not detected in the clinical isolates. Regarding usnic acid, it presented a moderate antibacterial activity against two P. aeruginosa isolates (MIC = 250 μg/mL) and no activity was detected against the others. A synergistic effect between usnic acid and polymyxin B was observed against three clinical isolates of P. aeruginosa which were resistant to polymyxin B (FICI ≤ 0.5). Therefore, it was possible to observe that usnic acid is a promising candidate to be used in combination with polymyxin B against infections caused by resistant P. aeruginosa.</description><subject>Acinetobacter</subject><subject>Antibacterial activity</subject><subject>Antimicrobial resistance</subject><subject>Bacteria</subject><subject>Bacteriology</subject><subject>Clinical isolates</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>Drug resistance in microorganisms</subject><subject>E coli</subject><subject>Genes</subject><subject>Gram-negative bacteria</subject><subject>Microorganisms</subject><subject>Minimum inhibitory concentration</subject><subject>Nosocomial infections</subject><subject>Pathogens</subject><subject>Polymerase chain reaction</subject><subject>Polymyxin B</subject><subject>Pseudomonas aeruginosa</subject><subject>Usnic acid</subject><issn>1741-427X</issn><issn>1741-4288</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqF0c1rFDEYBvBBFFurN88S8CLYtfmaSXIR1qXVQsGiFryFdzNvpikzSTuZse5_b5ZdWvTiKSH55UnCU1WvGf3AWF2fcMrpidE1Z7J-Uh0yJdlCcq2fPszVz4PqRc43lHKjlHpeHQiupTFUHVb5-ybi2IU8BUdOvUc3kTVO94iRXOVYFpcutARiSy5Tvxk2v0Mknwh0EGKeyDfM5SjEiaz6UDT05DynHibMJHlymXFu05AiZAI4zl2IKcPL6pmHPuOr_XhUXZ2d_lh9WVx8_Xy-Wl4snFTNtKjRq_J4h2uJrebCITdSgAQtHWpgHhrJWg8eHPeGa0eVUDV1jfFrr7gTR9XHXe7tvB6wdRinEXp7O4YBxo1NEOzfOzFc2y79skpKJpkoAe_2AWO6mzFPdgjZYd9DxDRny6VQWkplaKFv_6E3aR5j-d5WNaIgYx5VBz3aEH0q97ptqF02oghZ-inqeKfcmHIe0T88mVG77dxuO7f7zgt_v-PXIbZwH_6n3-w0FoMeHjWrtVK1-ANZKbWE</recordid><startdate>2020</startdate><enddate>2020</enddate><creator>Vieira Maciel, Maria Amélia</creator><creator>da Silva, Adriana Maria Costa Marques</creator><creator>da Silva, Wagner Roberto Cirilo</creator><creator>Costa-Junior, Sérgio Dias</creator><creator>Cavalcanti, Isabella Macário Ferro</creator><general>Hindawi Publishing Corporation</general><general>Hindawi</general><general>John Wiley & Sons, Inc</general><general>Hindawi Limited</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88G</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M2M</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7889-3502</orcidid><orcidid>https://orcid.org/0000-0002-2501-3284</orcidid></search><sort><creationdate>2020</creationdate><title>Synergistic Effect between Usnic Acid and Polymyxin B against Resistant Clinical Isolates of Pseudomonas aeruginosa</title><author>Vieira Maciel, Maria Amélia ; da Silva, Adriana Maria Costa Marques ; da Silva, Wagner Roberto Cirilo ; Costa-Junior, Sérgio Dias ; Cavalcanti, Isabella Macário Ferro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c476t-5ef7427ceb4ed823ce2943a4a84ce8a1fa641dfafac2f928c073750c69fbf72c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Acinetobacter</topic><topic>Antibacterial activity</topic><topic>Antimicrobial resistance</topic><topic>Bacteria</topic><topic>Bacteriology</topic><topic>Clinical isolates</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>Drug resistance in microorganisms</topic><topic>E coli</topic><topic>Genes</topic><topic>Gram-negative bacteria</topic><topic>Microorganisms</topic><topic>Minimum inhibitory concentration</topic><topic>Nosocomial infections</topic><topic>Pathogens</topic><topic>Polymerase chain reaction</topic><topic>Polymyxin B</topic><topic>Pseudomonas aeruginosa</topic><topic>Usnic acid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vieira Maciel, Maria Amélia</creatorcontrib><creatorcontrib>da Silva, Adriana Maria Costa Marques</creatorcontrib><creatorcontrib>da Silva, Wagner Roberto Cirilo</creatorcontrib><creatorcontrib>Costa-Junior, Sérgio Dias</creatorcontrib><creatorcontrib>Cavalcanti, Isabella Macário Ferro</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access Journals</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Evidence-based complementary and alternative medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vieira Maciel, Maria Amélia</au><au>da Silva, Adriana Maria Costa Marques</au><au>da Silva, Wagner Roberto Cirilo</au><au>Costa-Junior, Sérgio Dias</au><au>Cavalcanti, Isabella Macário Ferro</au><au>Kuete, Victor</au><au>Victor Kuete</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Synergistic Effect between Usnic Acid and Polymyxin B against Resistant Clinical Isolates of Pseudomonas aeruginosa</atitle><jtitle>Evidence-based complementary and alternative medicine</jtitle><date>2020</date><risdate>2020</risdate><volume>2020</volume><issue>2020</issue><spage>1</spage><epage>9</epage><pages>1-9</pages><issn>1741-427X</issn><eissn>1741-4288</eissn><abstract>The present study aimed to characterize the susceptibility profile of Pseudomonas aeruginosa and Acinetobacter spp. clinical isolates to polymyxin B in a public hospital in Recife-PE, Brazil, between the years of 2018 and 2019, as well as to search for the presence of the mcr-1 gene and evaluate the interaction between polymyxin B and usnic acid against these isolates. The strains were identified using the BD Phoenix™ automated system and the agar-spot test was used to determine the susceptibility profile to polymyxin B. The minimum inhibitory concentrations (MICs) of usnic acid and polymyxin B were determined through the broth microdilution method according to the Clinical and Laboratory Standards Institute (CLSI). Subsequently, Polymerase Chain Reaction (PCR) was performed to detect the mcr-1 gene in the isolates. The interaction between usnic acid and polymyxin B was evaluated by the Checkerboard assay. Among 34 isolates of P. aeruginosa, 26.5% (9/34) were positive for the polymyxin B agar-spot test, and 11.8% (4/34) presented an intermediate susceptibility (MIC = 4 μg/mL), while 14.7% (5/34) presented antimicrobial resistance with MIC values ranging from 8 to 32 μg/mL. Among 38 isolates of Acinetobacter spp., 13.2% (5/38) were positive for the polymyxin B agar-spot test and all of them were resistant to polymyxin B with a MIC value > 32 μg/mL. The mcr-1 gene was not detected in the clinical isolates. Regarding usnic acid, it presented a moderate antibacterial activity against two P. aeruginosa isolates (MIC = 250 μg/mL) and no activity was detected against the others. A synergistic effect between usnic acid and polymyxin B was observed against three clinical isolates of P. aeruginosa which were resistant to polymyxin B (FICI ≤ 0.5). Therefore, it was possible to observe that usnic acid is a promising candidate to be used in combination with polymyxin B against infections caused by resistant P. aeruginosa.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>32849907</pmid><doi>10.1155/2020/9852145</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-7889-3502</orcidid><orcidid>https://orcid.org/0000-0002-2501-3284</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1741-427X |
| ispartof | Evidence-based complementary and alternative medicine, 2020, Vol.2020 (2020), p.1-9 |
| issn | 1741-427X 1741-4288 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7441413 |
| source | PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; Wiley Online Library (Open Access Collection); PubMed Central; Alma/SFX Local Collection |
| subjects | Acinetobacter Antibacterial activity Antimicrobial resistance Bacteria Bacteriology Clinical isolates Deoxyribonucleic acid DNA Drug resistance in microorganisms E coli Genes Gram-negative bacteria Microorganisms Minimum inhibitory concentration Nosocomial infections Pathogens Polymerase chain reaction Polymyxin B Pseudomonas aeruginosa Usnic acid |
| title | Synergistic Effect between Usnic Acid and Polymyxin B against Resistant Clinical Isolates of Pseudomonas aeruginosa |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T11%3A09%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Synergistic%20Effect%20between%20Usnic%20Acid%20and%20Polymyxin%20B%20against%20Resistant%20Clinical%20Isolates%20of%20Pseudomonas%20aeruginosa&rft.jtitle=Evidence-based%20complementary%20and%20alternative%20medicine&rft.au=Vieira%20Maciel,%20Maria%20Am%C3%A9lia&rft.date=2020&rft.volume=2020&rft.issue=2020&rft.spage=1&rft.epage=9&rft.pages=1-9&rft.issn=1741-427X&rft.eissn=1741-4288&rft_id=info:doi/10.1155/2020/9852145&rft_dat=%3Cgale_pubme%3EA639994777%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2436347999&rft_id=info:pmid/32849907&rft_galeid=A639994777&rfr_iscdi=true |